Catalyst Income Before Tax vs Income Tax Expense Analysis

CPRX Stock  USD 22.11  0.37  1.70%   
Catalyst Pharmaceuticals financial indicator trend analysis is way more than just evaluating Catalyst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Catalyst Pharmaceuticals is a good investment. Please check the relationship between Catalyst Pharmaceuticals Income Before Tax and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Income Before Tax vs Income Tax Expense

Income Before Tax vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Catalyst Pharmaceuticals Income Before Tax account and Income Tax Expense. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Catalyst Pharmaceuticals' Income Before Tax and Income Tax Expense is 0.54. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Catalyst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Catalyst Pharmaceuticals' Income Before Tax and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Catalyst Pharmaceuticals are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Income Before Tax i.e., Catalyst Pharmaceuticals' Income Before Tax and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

0.54
Relationship DirectionPositive 
Relationship StrengthWeak

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Catalyst Pharmaceuticals income statement and is an important metric when analyzing Catalyst Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Income Tax Expense

Most indicators from Catalyst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Catalyst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.At this time, Catalyst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 19.7 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.11 in 2024.
 2023 2024 (projected)
Reconciled Depreciation24.4M25.6M
Net Interest Income1.8M1.0M

Catalyst Pharmaceuticals fundamental ratios Correlations

1.0-0.80.820.310.790.490.80.980.910.980.990.910.790.90.890.510.930.480.47-0.80.930.830.860.720.99
1.0-0.790.810.320.790.50.810.970.910.980.980.910.790.90.890.530.930.50.48-0.80.930.830.860.710.99
-0.8-0.79-1.0-0.65-0.99-0.63-0.74-0.79-0.97-0.73-0.75-0.81-0.52-0.47-0.44-0.6-0.77-0.61-0.540.33-0.63-0.35-0.82-0.88-0.84
0.820.81-1.00.640.990.620.750.810.970.750.770.830.540.50.470.590.790.60.54-0.360.650.380.830.880.86
0.310.32-0.650.640.650.460.390.230.550.250.210.310.12-0.01-0.030.40.260.430.480.130.3-0.180.530.470.42
0.790.79-0.990.990.650.690.790.770.970.720.730.810.460.450.420.660.770.670.57-0.330.610.350.790.860.84
0.490.5-0.630.620.460.690.860.440.660.390.440.46-0.080.330.210.980.430.980.39-0.310.450.270.560.380.56
0.80.81-0.740.750.390.790.860.740.840.710.760.710.270.680.590.870.710.870.46-0.620.760.630.760.50.84
0.980.97-0.790.810.230.770.440.740.90.970.990.90.810.880.880.450.920.420.39-0.780.890.820.850.770.96
0.910.91-0.970.970.550.970.660.840.90.860.870.890.610.660.630.640.870.640.56-0.540.770.560.870.850.95
0.980.98-0.730.750.250.720.390.710.970.860.980.890.850.90.920.410.920.370.43-0.810.90.850.80.720.96
0.990.98-0.750.770.210.730.440.760.990.870.980.890.810.920.910.460.920.430.39-0.820.920.860.860.70.96
0.910.91-0.810.830.310.810.460.710.90.890.890.890.730.730.740.450.990.430.74-0.640.750.670.810.70.91
0.790.79-0.520.540.120.46-0.080.270.810.610.850.810.730.750.84-0.050.77-0.10.3-0.650.720.70.610.620.74
0.90.9-0.470.5-0.010.450.330.680.880.660.90.920.730.750.980.380.790.330.25-0.940.940.970.740.410.85
0.890.89-0.440.47-0.030.420.210.590.880.630.920.910.740.840.980.260.810.210.26-0.920.910.970.680.430.84
0.510.53-0.60.590.40.660.980.870.450.640.410.460.45-0.050.380.260.430.990.36-0.330.480.330.540.340.58
0.930.93-0.770.790.260.770.430.710.920.870.920.920.990.770.790.810.430.410.69-0.710.790.750.820.670.93
0.480.5-0.610.60.430.670.980.870.420.640.370.430.43-0.10.330.210.990.410.37-0.280.440.280.520.330.55
0.470.48-0.540.540.480.570.390.460.390.560.430.390.740.30.250.260.360.690.37-0.210.330.20.520.280.53
-0.8-0.80.33-0.360.13-0.33-0.31-0.62-0.78-0.54-0.81-0.82-0.64-0.65-0.94-0.92-0.33-0.71-0.28-0.21-0.84-0.95-0.6-0.31-0.74
0.930.93-0.630.650.30.610.450.760.890.770.90.920.750.720.940.910.480.790.440.33-0.840.860.870.490.91
0.830.83-0.350.38-0.180.350.270.630.820.560.850.860.670.70.970.970.330.750.280.2-0.950.860.60.310.77
0.860.86-0.820.830.530.790.560.760.850.870.80.860.810.610.740.680.540.820.520.52-0.60.870.60.630.89
0.720.71-0.880.880.470.860.380.50.770.850.720.70.70.620.410.430.340.670.330.28-0.310.490.310.630.73
0.990.99-0.840.860.420.840.560.840.960.950.960.960.910.740.850.840.580.930.550.53-0.740.910.770.890.73
Click cells to compare fundamentals

Catalyst Pharmaceuticals Account Relationship Matchups

Catalyst Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets112.4M192.4M237.8M375.6M470.1M493.6M
Total Stockholder Equity87.6M169.6M206.8M300.4M387.9M407.3M
Net Debt(88.9M)(130.2M)(167.6M)(294.5M)(134.1M)(127.4M)
Cash89.5M130.2M171.4M298.4M137.6M144.5M
Cash And Short Term Investments94.5M140.3M191.3M298.4M137.6M144.5M
Common Stock Shares Outstanding106.0M106.2M107.8M111.4M113.8M57.0M
Liabilities And Stockholders Equity112.4M192.4M237.8M375.6M470.1M493.6M
Other Stockholder Equity216.2M223.2M233.2M250.4M266.5M279.8M
Total Liab24.7M22.8M31.0M75.2M82.2M86.3M
Total Current Assets111.4M159.2M210.1M320.8M219.3M230.3M
Other Current Liab172.3K18.5M23.9M44.6M60.2M63.2M
Total Current Liabilities24.1M22.8M27.1M57.6M76.1M79.9M
Property Plant And Equipment Net1.0M129.8K4.0M3.6M3.7M3.9M
Retained Earnings(128.7M)(53.7M)(26.3M)49.9M121.3M127.3M
Accounts Payable4.1M4.3M2.8M4.0M14.8M15.5M
Non Current Assets Total1.0M33.1M27.7M54.8M250.8M263.3M
Common Stock Total Equity103.4K103.8K103K105K120.8K66.6K
Property Plant And Equipment Gross1.0M129.8K4.0M3.6M4.4M4.6M
Accumulated Other Comprehensive Income9.5K31.3K(148K)24K14K14.7K
Common Stock103.4K103.8K103K105K107K69.1K
Property Plant Equipment210.5K129.8K4.0M847K974.1K1.0M
Other Current Assets4.4M8.3M4.4M5.2M12.5M13.2M
Non Current Liabilities Total647.5K4.3M3.9M17.6M6.2M6.5M
Net Tangible Assets87.6M169.6M206.8M268.0M308.1M323.5M
Retained Earnings Total Equity(160.6M)(128.7M)(26.3M)49.9M57.3M60.2M
Capital Surpluse211.3M216.2M233.2M250.4M288.0M169.1M
Inventory2.0M4.7M7.9M6.8M15.6M16.4M
Non Current Liabilities Other154.8K647.5K3.9M17.6M485K460.8K
Net Invested Capital87.6M169.6M206.8M300.4M387.9M201.8M
Net Working Capital87.3M136.5M183.0M263.2M143.3M147.7M
Capital Stock103.4K103.8K103K105K107K114.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.